Here are the 10-Q quarterly reports from Hologic Inc (HOLX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HOLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HOLX filings page.
Hologic reported modest revenue growth but lower profit while preparing to go private in a major buyout. Quarterly revenue rose to $1,047.8 million from $1,021.8 million, driven by higher GYN Surgical and Skeletal Health sales. Net income declined to $179.1 million from $201.0 million, with diluted EPS down to $0.79 from $0.87.
Diagnostics revenue was essentially flat as lower COVID and certain STI testing offset growth in vaginitis and open-access assays. Breast Health dipped, including a recall-driven halt of Brevera 9 Gauge needles, while GYN Surgical benefited from the $340.7 million Gynesonics acquisition. Cash and cash equivalents increased to $2,168.0 million.
Hologic also agreed to be acquired by funds managed by Blackstone and TPG for $76.00 per share in cash plus a non-tradable contingent value right of up to $3.00 per share, tied to Breast Health revenue targets in fiscal 2026–2027. The deal is expected to close in the first half of 2026, after shareholder and regulatory approvals, and would result in Hologic’s Nasdaq delisting. A major BioZorb product-liability case was settled with the amount fully covered by insurance.
Hologic (HOLX) Q3 FY25 10-Q highlights: Revenue edged up 1.2% YoY to $1.024 bn, with U.S. sales flat and Europe +16% offsetting a 7% decline in Asia-Pac. Diagnostics grew 2% to $449 m and GYN Surgical +7% to $178 m, while Breast Health fell 5% to $365 m. Gross margin improved 100 bp to 56.4%, lifting operating income 4% to $254.6 m. Net income was stable at $194.9 m; diluted EPS rose 5% to $0.86 on a 5% lower share count.
Year-to-date revenue was flat at $3.05 bn, but $221 m of intangible impairments pushed net income down 38% to $378.5 m (EPS $1.66). Operating cash flow fell 24% to $702 m, while the company spent $753 m on share buybacks and $322 m on acquisitions, cutting cash to $1.74 bn (-$425 m since Sept-24). Debt remains ~ $2.5 bn; on 15 Jul 25 HOLX refinanced its credit facility, trimming the term loan to $1.17 bn and keeping a $1.25 bn revolver.
Balance-sheet leverage is modest (net cash > $-0.4 bn) and equity totals $4.84 bn. Remaining performance obligations stand at $898 m, 58% due within three years. Management continues portfolio pruning (SSI divestiture) and expansion (Gynesonics $341 m, Endomag $314 m) while absorbing restructuring costs ($17.6 m YTD).